Table 2.
Study Population Phenotypes and Diagnoses
| Poss-AE (n = 206) | Non-AE (n = 139) | |
|---|---|---|
| Oligo-amenorrhea only (%) | 35/206 (17.0%) | 0/139 (0%) |
| Hirsutism only (%) | 46/206 (22.3%) | 19/139 (13.7%) |
| PCOM only (%) | 9/206 (4.4%) | 41/139 (29.4%) |
| Oligo-amenorrhea + Hirsutism + PCOM (%) | 83 (40.2%) | 1/139 (0.7%) |
| Oligo-amenorrhea + Hirsutism (%) | 11/206 (5.3%) | 0/139 (0%) |
| Oligo-amenorrhea + PCOM (%) | 24/206 (11.7%) | 0/139 (0%) |
| Hirsutism + PCOM (%) | 34/206 (16.5%) | 10/139 (7.2%) |
| PCOS by Rotterdam criteria (2003)c (%) | 170/206 (82.5%) | 22/139 (15.8%) |
| NCAH (%) | 1/206 (0.5%) | 0/139 (0%) |
| Hyperprolactinemia (%) | 3/206 (1.5%) | 2/139 (1.4%) |
| Thyroid abnormality (%) | 4/206 (1.9%) | 2/139 (1.4%) |
| Free testosterone (pg/mL) mean ± SD | 5.2 ± 3.7 | 2.4 ± 1.9b |
| Total testosterone (pg/mL) mean ± SD | 40.9 ± 25.8 | 26.5 ± 14.3b |
| DHEAS (ug/dL) mean ± SD | 241.1 ± 118.6 | 193.3 ± 98.9a |
Abbreviations: DHEAS, dehydroepiandrosterone sulfate; NCAH, non-classic adrenal hyperplasia; Non-AE, probably no androgen excess disorder; PCOM, polycystic ovarian morphology; Poss-AE, possible androgen excess disorder; SD, standard deviation.
a P < 0.05 as compared with the Poss-AE group
b P < 0.0001 as compared with the Poss-AE group
cTwo of the following 3 criteria: oligo-amenorrhea, hyperandrogenism, or polycystic ovarian morphology